Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.41 |
| ▸ | RPS6KB2 | Q9UBS0 | 1/20 | 0.34 |
| ▸ | CYP11B1 | P15538 | 4/20 | 0.32 |
| ▸ | CYP11B2 | P19099 | 4/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10312548 | 0.81 | HCAR2 (0.46) | HCAR2RPS6KB2CYP11B1CYP11B2 | |
| SCHEMBL4548441 | 0.80 | CRBN (0.36) | — | |
| SCHEMBL4548440 | 0.77 | HDAC3 (0.38) | — | |
| SCHEMBL4548437 | 0.75 | KCNJ1 (0.42) | — | |
| SCHEMBL5163659 | 0.69 | ALDH1A1 (0.43) | — | |
| SCHEMBL15825442 | 0.69 | RPS6KB2 (0.44) | RPS6KB2CYP11B1CYP11B2 | |
| Hydrochloric Acid SCHEMBL5163653 | 0.69 | ALDH1A1 (0.42) | — | |
| SCHEMBL13091417 | 0.69 | RPS6KB2 (0.44) | RPS6KB2CYP11B1CYP11B2 | |
| Hydrochloric Acid SCHEMBL5160828 | 0.68 | HRH3 (0.38) | HCAR2RPS6KB2CYP11B1CYP11B2 | |
| SCHEMBL7535671 | 0.68 | F2RL1 (0.46) | CYP11B1CYP11B2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8168649-B2 | Niacin receptor agonists, compositions containing such compounds and methods of treatment | Merk Sharp & Dohme Corp. (US) | 2012-05-01 | — | — | US | disclosed |
| US-20100144778-A1 | Niacin Receptor Agonists, Compositions Containing Such Compounds and Methods of Treatment | MERCK SHARP & DOHME LLC | 2010-06-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100144778-A1 | Niacin Receptor Agonists, Compositions Containing Such Compounds and Methods of Treatment | HCAR1, HCAR2, GPR119 | HCAR2 2/4885RPS6KB2 4224/4885CYP11B1 417/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.